Arca
Skip to content
Tools
Tools

-tinib

A tyrosine kinase inhibitor: a small molecule that blocks one of the enzymes cells use to pass on growth signals. Many are cancer drugs.

  • Drugs ending in -tinib: 244
  • Approved somewhere: 63
  • With a US drug page: 66

What it means

Stem from WHO's stem book, 2024; description by Arca
Stem
-tinib
Class
Small molecules that block tyrosine kinases, the switches for many growth signals
Most common targets
EGFR (32), BTK (17), KIT (16), FLT3 (14), ERBB2 (13), MET (13), KDR (11), JAK1 (11)

Drugs that carry it

Approved and clinical-stage drugs in ChEMBL whose names ending in -tinib or one of its sub-stems, matched by spelling; those with a US drug page link to it.
Acts on
AfatinibApprovedEGFR, ERBB2, ERBB4Epidermal growth factor receptor erbB1 inhibitor
AlectinibApprovedALK, RET, ALK, EML4ALK tyrosine kinase receptor inhibitor
AvapritinibApprovedKIT, PDGFRAStem cell growth factor receptor inhibitor
AxitinibApprovedVascular endothelial growth factor receptorVascular endothelial growth factor receptor inhibitor
BosutinibApprovedABL1, SRC, HCK, LYN and 1 moreTyrosine-protein kinase ABL inhibitor
BrigatinibApprovedALK, EGFRALK tyrosine kinase receptor inhibitor
CabozantinibApprovedKDR, METVascular endothelial growth factor receptor 2 inhibitor
CapmatinibApprovedMETHepatocyte growth factor receptor inhibitor
CeritinibApprovedALK, ALK, EML4, ALK, NPM1ALK tyrosine kinase receptor inhibitor
CrizotinibApprovedMET, ALK, ALK, EML4, ALK, NPM1 and 2 moreHepatocyte growth factor receptor inhibitor
ErdafitinibApprovedFibroblast growth factor receptorFibroblast growth factor receptor inhibitor
ErlotinibApprovedEGFREpidermal growth factor receptor erbB1 inhibitor
FedratinibApprovedFLT3, JAK2Tyrosine-protein kinase receptor FLT3 inhibitor
FostamatinibApprovedSYKTyrosine-protein kinase SYK inhibitor
FruquintinibApprovedVascular endothelial growth factor receptorVascular endothelial growth factor receptor inhibitor
FutibatinibApprovedFibroblast growth factor receptorFibroblast growth factor receptor inhibitor
GefitinibApprovedEGFREpidermal growth factor receptor erbB1 inhibitor
GilteritinibApprovedFLT3, AXLTyrosine-protein kinase receptor FLT3 inhibitor
ImatinibApprovedABL1, PDGFRB, KIT, ABL1, BCRTyrosine-protein kinase ABL inhibitor
InfigratinibApprovedFibroblast growth factor receptorFibroblast growth factor receptor inhibitor
LapatinibApprovedERBB2, EGFRReceptor protein-tyrosine kinase erbB-2 inhibitor
LenvatinibApprovedVascular endothelial growth factor receptorVascular endothelial growth factor receptor inhibitor
LorlatinibApprovedALK, ALK, EML4ALK tyrosine kinase receptor inhibitor
MomelotinibApprovedJAK1, JAK2, ACVR1Tyrosine-protein kinase JAK1 inhibitor
NeratinibApprovedEGFR, ERBB2, ERBB4Epidermal growth factor receptor erbB1 inhibitor
PacritinibApprovedJAK2, FLT3, ACVR1, IRAK1Tyrosine-protein kinase JAK2 inhibitor
PemigatinibApprovedFGFR2, FGFR3, FGFR1Fibroblast growth factor receptor 2 inhibitor
PexidartinibApprovedCSF1R, FLT3, KITMacrophage colony stimulating factor receptor inhibitor
PonatinibApprovedABL1, BCRBcr/Abl fusion protein inhibitor
PralsetinibApprovedRET, CCDC6, RET, KIF5B, RETTyrosine-protein kinase receptor RET inhibitor
QuizartinibApprovedCSF1R, FLT3, KIT, PDGFRA, PDGFRB and 1 moreMacrophage colony stimulating factor receptor inhibitor
RipretinibApprovedKIT, PDGFRAStem cell growth factor receptor inhibitor
SelpercatinibApprovedRET, KIF5B, RET, CCDC6, RETTyrosine-protein kinase receptor RET inhibitor
SunitinibApprovedCSF1R, KIT, FLT3, PDGFRA, PDGFRB and 7 moreMacrophage colony stimulating factor receptor inhibitor
TepotinibApprovedMETHepatocyte growth factor receptor inhibitor
TucatinibApprovedERBB2Receptor protein-tyrosine kinase erbB-2 inhibitor
EnsartinibPhase 3ALKALK tyrosine kinase receptor inhibitor
PimicotinibPhase 3——
VimseltinibPhase 3——
ZidesamtinibPhase 2——
LirafugratinibPhase 1——
Dacomitinib anhydrousApprovedEGFR, ERBB2, ERBB4Epidermal growth factor receptor erbB1 inhibitor
Dasatinib anhydrousApprovedABL1, PDGFRB, KIT, EPHA2 and 2 moreTyrosine-protein kinase ABL inhibitor
FilgotinibApprovedJAK1, JAK2, TYK2, JAK3Tyrosine-protein kinase JAK1 inhibitor
MasitinibApprovedFGFR3, KIT, PDGFRA, PDGFRBFibroblast growth factor receptor 3 inhibitor
NilotinibApprovedABL1, ABL1, BCRTyrosine-protein kinase ABL inhibitor
OlmutinibApprovedEGFREpidermal growth factor receptor erbB1 inhibitor
RuxolitinibApprovedJAK1, JAK2, JAK3, TYK2Tyrosine-protein kinase JAK1 inhibitor
CatequentinibPhase 3KDR, FLT4, KIT, PDGFRBVascular endothelial growth factor receptor 2 inhibitor
DefactinibPhase 3PTK2, PTK2BFocal adhesion kinase 1 inhibitor
DovitinibPhase 3FGFR3, FLT3, KIT, PDGFRA, PDGFRB and 1 moreFibroblast growth factor receptor 3 inhibitor
EntospletinibPhase 3SYKTyrosine-protein kinase SYK inhibitor
FamitinibPhase 3KIT, FLT1, FLT3, PDGFRA, PDGFRB and 2 moreStem cell growth factor receptor inhibitor
FlumatinibPhase 3ABL1Tyrosine-protein kinase ABL inhibitor
IcotinibPhase 3EGFREpidermal growth factor receptor erbB1 inhibitor
LestaurtinibPhase 3FLT3, JAK2, NTRK1, NTRK2 and 2 moreTyrosine-protein kinase receptor FLT3 inhibitor
LinsitinibPhase 3IGF1R, INSRInsulin-like growth factor I receptor inhibitor
NaquotinibPhase 3EGFREpidermal growth factor receptor erbB1 inhibitor
OlverembatinibPhase 3ABL1, BCRBcr/Abl fusion protein inhibitor
OrantinibPhase 3Fibroblast growth factor receptor, PDGFRA, PDGFRB, KDRFibroblast growth factor receptor inhibitor
PoziotinibPhase 3Epidermal growth factor receptorEpidermal growth factor receptor inhibitor
PyrotinibPhase 3EGFR, ERBB2Epidermal growth factor receptor erbB1 inhibitor
RadotinibPhase 3ABL1, BCRBcr/Abl fusion protein inhibitor
RociletinibPhase 3EGFREpidermal growth factor receptor erbB1 inhibitor
RuserontinibPhase 3EGFR, FLT3, ABL1Epidermal growth factor receptor erbB1 inhibitor
SavolitinibPhase 3METHepatocyte growth factor receptor inhibitor
SeralutinibPhase 3KIT, PDGFRA, PDGFRB, CSF1RStem cell growth factor receptor inhibitor
SitravatinibPhase 3——
SurufatinibPhase 3FGFR1, Vascular endothelial growth factor receptorFibroblast growth factor receptor 1 inhibitor
TesevatinibPhase 3EPHB4, EGFR, ERBB2Ephrin type-B receptor 4 inhibitor
TinengotinibPhase 3——
TivantinibPhase 3METHepatocyte growth factor receptor inhibitor
ZanzalintinibPhase 3——
AdrixetinibPhase 2——
AllitinibPhase 2EGFR, ERBB2Epidermal growth factor receptor erbB1 inhibitor
AmuvatinibPhase 2FLT3, KIT, MET, PDGFRATyrosine-protein kinase receptor FLT3 inhibitor
BafetinibPhase 2ABL1, LYNTyrosine-protein kinase ABL inhibitor
BemcentinibPhase 2AXLTyrosine-protein kinase receptor UFO inhibitor
BezuclastinibPhase 2——
CanlitinibPhase 2——
CerdulatinibPhase 2SYK, JAK1, JAK3, TYK2Tyrosine-protein kinase SYK inhibitor
DalmelitinibPhase 2——
DecernotinibPhase 2JAK3Tyrosine-protein kinase JAK3 inhibitor
DenfivontinibPhase 2——
DerazantinibPhase 2Fibroblast growth factor receptorFibroblast growth factor receptor inhibitor
EdicotinibPhase 2CSF1RMacrophage colony stimulating factor receptor inhibitor
ElenestinibPhase 2——
EnrupatinibPhase 2——
FanregratinibPhase 2——
FexagratinibPhase 2Fibroblast growth factor receptorFibroblast growth factor receptor inhibitor
ForetinibPhase 2FLT3, KIT, MET, PDGFRA, PDGFRB and 2 moreTyrosine-protein kinase receptor FLT3 inhibitor
GandotinibPhase 2JAK2Tyrosine-protein kinase JAK2 inhibitor
GlesatinibPhase 2MET, MST1R, Vascular endothelial growth factor receptor, TEKHepatocyte growth factor receptor inhibitor
GumarontinibPhase 2——
IfebemtinibPhase 2PTK2Focal adhesion kinase 1 inhibitor
LunbotinibPhase 2——
MerestinibPhase 2METHepatocyte growth factor receptor inhibitor
MivavotinibPhase 2SYKTyrosine-protein kinase SYK inhibitor
MobinitinibPhase 2——
NarmafotinibPhase 2——
NazartinibPhase 2EGFREpidermal growth factor receptor erbB1 inhibitor
NefextinibPhase 2——
NingetinibPhase 2MET, KDR, MERTK, FLT3 and 1 moreHepatocyte growth factor receptor inhibitor
OritinibPhase 2——
PegcantratinibPhase 2NTRK1Nerve growth factor receptor Trk-A inhibitor
PelitinibPhase 2EGFREpidermal growth factor receptor erbB1 inhibitor
PoseltinibPhase 2BTKTyrosine-protein kinase BTK inhibitor
ResencatinibPhase 2——
ResigratinibPhase 2——
RisvodetinibPhase 2——
RogaratinibPhase 2Fibroblast growth factor receptorFibroblast growth factor receptor inhibitor
SapitinibPhase 2ERBB2, ERBB3, EGFRReceptor protein-tyrosine kinase erbB-2 inhibitor
SaracatinibPhase 2ABL1, SRCTyrosine-protein kinase ABL inhibitor
SegigratinibPhase 2——
SoxataltinibPhase 2——
TamnorzatinibPhase 2——
TandutinibPhase 2FLT3, KIT, PDGFRBTyrosine-protein kinase receptor FLT3 inhibitor
TarloxotinibPhase 2Epidermal growth factor receptorEpidermal growth factor receptor inhibitor
TelatinibPhase 2KIT, PDGFRB, KDR, FLT4Stem cell growth factor receptor inhibitor
UnecritinibPhase 2——
VamotinibPhase 2——
VarlitinibPhase 2EGFR, ERBB2Epidermal growth factor receptor erbB1 inhibitor
VeonetinibPhase 2——
VodobatinibPhase 2ABL1, ABL1, BCRTyrosine-protein kinase ABL inhibitor
AltiratinibPhase 1MET, TEK, KDR, Neurotrophic tyrosine kinase receptorHepatocyte growth factor receptor inhibitor
ConteltinibPhase 1PTK2, IGF1R, ALK, PTK2BFocal adhesion kinase 1 inhibitor
DubermatinibPhase 1——
ElzovantinibPhase 1——
EnbezotinibPhase 1——
EpitinibPhase 1EGFREpidermal growth factor receptor erbB1 inhibitor
FisogatinibPhase 1——
GolvatinibPhase 1MET, KDRHepatocyte growth factor receptor inhibitor
HenatinibPhase 1KDRVascular endothelial growth factor receptor 2 inhibitor
LuxeptinibPhase 1——
MubritinibPhase 1ERBB2Receptor protein-tyrosine kinase erbB-2 inhibitor
RebastinibPhase 1ABL1Tyrosine-protein kinase ABL inhibitor
SimotinibPhase 1EGFREpidermal growth factor receptor erbB1 inhibitor
SoquelitinibPhase 1——
SotuletinibPhase 1——
TafetinibPhase 1——
TheliatinibPhase 1EGFREpidermal growth factor receptor erbB1 inhibitor
TuspetinibPhase 1——
VebreltinibPhase 1——
ZeteletinibPhase 1——
Puquitinib—PI3-kinase class I, EGFR, KDR, PDGFRBPI3-kinase class I inhibitor
IbrutinibApprovedBTKTyrosine-protein kinase BTK inhibitor
PirtobrutinibApprovedBTKTyrosine-protein kinase BTK inhibitor
ZanubrutinibApprovedBTKTyrosine-protein kinase BTK inhibitor
RemibrutinibPhase 3——
RilzabrutinibPhase 3BTKTyrosine-protein kinase BTK inhibitor
AcalabrutinibApprovedBTKTyrosine-protein kinase BTK inhibitor
EvobrutinibPhase 3BTKTyrosine-protein kinase BTK inhibitor
FenebrutinibPhase 3BTKTyrosine-protein kinase BTK inhibitor
NemtabrutinibPhase 3——
OrelabrutinibPhase 3BTKTyrosine-protein kinase BTK inhibitor
TolebrutinibPhase 3BTKTyrosine-protein kinase BTK inhibitor
AtuzabrutinibPhase 2——
CinsebrutinibPhase 2——
CivorebrutinibPhase 2——
EdralbrutinibPhase 2BTKTyrosine-protein kinase BTK inhibitor
ElsubrutinibPhase 2BTKTyrosine-protein kinase BTK inhibitor
MilrebrutinibPhase 2——
RocbrutinibPhase 2——
SofnobrutinibPhase 2——
SpebrutinibPhase 2BTKTyrosine-protein kinase BTK inhibitor
TirabrutinibPhase 2BTKTyrosine-protein kinase BTK inhibitor
BranebrutinibPhase 1BTKTyrosine-protein kinase BTK inhibitor
VecabrutinibPhase 1BTKTyrosine-protein kinase BTK inhibitor
AbrocitinibApprovedJAK1Tyrosine-protein kinase JAK1 inhibitor
BaricitinibApprovedJAK1, JAK2Tyrosine-protein kinase JAK1 inhibitor
RitlecitinibApprovedJAK3, TEC family kinaseTyrosine-protein kinase JAK3 inhibitor
TofacitinibApprovedJanus Kinase (JAK)Janus Kinase (JAK) inhibitor
UpadacitinibApprovedTYK2, JAK3, JAK2, JAK1Tyrosine-protein kinase TYK2 inhibitor
BrepocitinibPhase 3TYK2, JAK1Tyrosine-protein kinase TYK2 inhibitor
DelgocitinibPhase 3Janus Kinase (JAK)Janus Kinase (JAK) inhibitor
CravacitinibApprovedTYK2Tyrosine-protein kinase TYK2 negative allosteric modulator
ItacitinibPhase 3JAK1Tyrosine-protein kinase JAK1 inhibitor
IvarmacitinibPhase 3——
PeficitinibPhase 3Janus Kinase (JAK)Janus Kinase (JAK) inhibitor
PovorcitinibPhase 3——
ZasocitinibPhase 3——
CenacitinibPhase 2——
EnvucitinibPhase 2——
FrevecitinibPhase 2——
GirocitinibPhase 2——
GolidocitinibPhase 2JAK1Tyrosine-protein kinase JAK1 inhibitor
GusacitinibPhase 2Janus Kinase (JAK), SYKJanus Kinase (JAK) inhibitor
IfidancitinibPhase 2——
IzencitinibPhase 2Janus Kinase (JAK)Janus Kinase (JAK) inhibitor
LepzacitinibPhase 2——
LomecitinibPhase 2——
PumecitinibPhase 2——
RopsacitinibPhase 2TYK2Tyrosine-protein kinase TYK2 inhibitor
RovadicitinibPhase 2——
SolcitinibPhase 2JAK1Tyrosine-protein kinase JAK1 inhibitor
ZemprocitinibPhase 2——
MilpecitinibPhase 1——
NezulcitinibPhase 1Janus Kinase (JAK)Janus Kinase (JAK) inhibitor
Oclacitinib—Janus kinase 1Janus kinase 1 inhibitor
LazertinibApprovedEGFREpidermal growth factor receptor erbB1 inhibitor
MobocertinibApprovedEGFREpidermal growth factor receptor erbB1 inhibitor
OsimertinibApprovedEGFREpidermal growth factor receptor erbB1 inhibitor
SunvozertinibPhase 3——
SevabertinibPhase 2——
ZongertinibPhase 1——
AbivertinibPhase 3EGFR, BTKEpidermal growth factor receptor erbB1 inhibitor
AumolertinibPhase 3EGFREpidermal growth factor receptor erbB1 inhibitor
FirmonertinibPhase 3EGFREpidermal growth factor receptor erbB1 inhibitor
RezivertinibPhase 3——
BefotertinibPhase 2——
CanertinibPhase 2EGFR, ERBB2, ERBB4Epidermal growth factor receptor erbB1 inhibitor
MifanertinibPhase 2——
SacibertinibPhase 2——
TigozertinibPhase 2——
UlixertinibPhase 2MAPK3, MAPK1MAP kinase ERK1 inhibitor
MavelertinibPhase 1EGFREpidermal growth factor receptor erbB1 inhibitor
PebezertinibPhase 1——
RavoxertinibPhase 1MAPK3, MAPK1MAP kinase ERK1 inhibitor
TuxobertinibPhase 1ERBB2, EGFRReceptor protein-tyrosine kinase erbB-2 negative allosteric modulator
BinimetinibApprovedMAP2K1, MAP2K2Dual specificity mitogen-activated protein kinase kinase 1 inhibitor
CobimetinibApprovedMAP2K1, MAP2K2Dual specificity mitogen-activated protein kinase kinase 1 inhibitor
TrametinibApprovedMAP2K2, MAP2K1, MAP2K1, MAP2K2Dual specificity mitogen-activated protein kinase kinase 2 inhibitor
MirdametinibPhase 2MAP2K1, MAP2K2Dual specificity mitogen-activated protein kinase kinase 1 inhibitor
SelumetinibApprovedMAP2K1, MAP2K2Dual specificity mitogen-activated protein kinase kinase 1 inhibitor
AvutometinibPhase 3MAP2K1, MAP2K2Dual specificity mitogen-activated protein kinase kinase 1 inhibitor
TunlametinibPhase 3——
GamcemetinibPhase 2——
LuvometinibPhase 2——
NedometinibPhase 2——
RalimetinibPhase 2MAPK14MAP kinase p38 alpha inhibitor
RefametinibPhase 2MAP2K1, MAP2K2Dual specificity mitogen-activated protein kinase kinase 1 inhibitor
ZapnometinibPhase 2——
ZunsemetinibPhase 2——
PexmetinibPhase 1MAPK14, TEKMAP kinase p38 alpha inhibitor
EntrectinibApprovedNeurotrophic tyrosine kinase receptor, ROS1, ALKNeurotrophic tyrosine kinase receptor inhibitor
LarotrectinibApprovedNeurotrophic tyrosine kinase receptorNeurotrophic tyrosine kinase receptor inhibitor
RepotrectinibApprovedNTRK1, NTRK2, ROS1, NTRK3 and 2 moreNerve growth factor receptor Trk-A inhibitor
AnizatrectinibPhase 2——
BoditrectinibPhase 2——
EmzeltrectinibPhase 2——
TaletrectinibPhase 2ROS1, Neurotrophic tyrosine kinase receptorProto-oncogene tyrosine-protein kinase ROS inhibitor
PaltimatrectinibPhase 1——
SelitrectinibPhase 1Neurotrophic tyrosine kinase receptorNeurotrophic tyrosine kinase receptor inhibitor
ZurletrectinibPhase 1——

Stem from WHO, The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances (2024); description written by Arca. Drugs, stages, targets and mechanisms from ChEMBL (CC BY-SA 3.0). WHO

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.